NCT01302860 - Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Cryopyrin-associated Periodic SyndromesFamilial Cold Autoinflammatory SyndromeMuckle-Wells SyndromeNeonatal Onset Multisystem Inflammatory Disease

Interventions

DRUG

ACZ885

Trial Locations (12)

Novartis Investigative Site, Lausanne

Novartis Investigative Site, Laken

Novartis Investigative Site, Brussels

Novartis Investigative Site, Berlin

Novartis Investigative Site, Granada

Novartis Investigative Site, Valencia

Novartis Investigative Site, Sankt Augustin

Novartis Investigative Site, Tübingen

Novartis Investigative Site, Le Kremlin-Bicêtre

Novartis Investigative Site, Toronto

Novartis Investigative Site, Dresden

Novartis Investigative Site, London